Surgical drape antistatic and low-flocculus-falling surface treatment process

Abstract

The invention discloses an anti-static and low-flocculus-falling surface treatment process for a surgical drape, and relates to the field of layered products, the treatment process comprises the following steps: S1, treating the surgical drape by adopting dielectric barrier discharge plasma; s2, applying an antistatic agent solution by adopting a padding method or a spraying method; s3, uniformly spraying an end-capping reagent solution on the surface of the sheet treated in the step S2; s4, performing steam sterilization, and cooling to obtain the antistatic low-flocculus-falling surgical drape. A low-melting-point polymer is compounded with a water-soluble end-capping reagent, high-pressure steam sterilization is combined, after the low-melting-point polymer is in contact with the surface of a paving sheet, the low-melting-point polymer can migrate to the tail end under the capillary action of the fiber surface, meanwhile, a film-forming agent is assisted to instantly swell when encountering water vapor, the polymer is guided to wrap a breaking point at the tail end of the fiber, and after cooling, the polymer is solidified to form a microspherical mechanical lock; the physical coating mechanism is more thorough in control of fallen flocculus, so that the risk of foreign body reaction or infection caused by fallen flocculus of an operation wound is further reduced.

Description

Technical Field

[0001] The invention relates to the technical field of layered products, in particular to a surface treatment process for a surgical drape that is anti-static and has low linting. Background Art

[0002] In the operating room environment, surgical drapes are the core consumables for constructing a sterile environment in the operating room. They are key barrier materials for isolating pathogenic microorganisms and maintaining the cleanliness of the surgical area. Currently, synthetic fiber drapes (such as polypropylene PP, polyethylene PE, and polyethylene terephthalate PET) are widely used in clinical practice. They have gradually replaced traditional cotton materials due to their advantages such as high mechanical strength, good breathability, and controllable costs.

[0003] However, the low surface energy of synthetic fibers makes them highly susceptible to static electricity accumulation in the dry operating room environment (relative humidity often below 40%) due to dynamic contact such as friction during medical staff manipulation and instrument placement. This leads to high static voltage on the drape surface. This static electricity not only attracts airborne dust particles, microbial spores, and surgical powders, creating a potential source of contamination in the surgical area, but can also interfere with the signal stability of precision electronic equipment such as electrosurgical units.

[0004] At the same time, during the repeated folding and instrument dragging process of surgical drapes, the fiber ends are prone to breakage and falling off due to mechanical stress, forming micron-sized fluff (mostly 5-100μm in diameter). If the fluff falls to the surface of the surgical wound, it may cause foreign body reaction, inflammatory reaction or postoperative infection, significantly increasing the risk of postoperative complications.

[0005] Therefore, it is necessary to improve the deficiencies in the prior art to solve the above problems. Summary of the Invention

[0006] The present invention overcomes the deficiencies of the prior art and provides a surface treatment process for a surgical drape with anti-static and low-linting properties.

[0007] To achieve the above object, the present invention adopts a technical solution: a surface treatment process for anti-static and low-linting surgical drapes, comprising the following steps: S1. Treat surgical drapes using dielectric barrier discharge plasma. S2. Apply an antistatic agent solution to the sheet treated in step S1 by padding or spraying, and react at 80-120°C for 3-10 minutes; S3. Spraying a capping agent solution uniformly on the surface of the drape treated in step S2 by ultrasonic atomization spraying; the capping agent solution comprises 3-8 wt% of a low melting point polymer, 0.1-0.5 wt% of an auxiliary film-forming agent, and a solvent; S4. The drape treated in step S3 is sterilized by high-pressure steam at 117-125° C. to melt the low-melting-point polymer and migrate to the fiber ends. After cooling, an antistatic and low-linting surgical drape is obtained.

[0008] In a preferred embodiment of the present invention, in step S3, the low melting point polymer is one of polyethylene glycol with a molecular weight of 1500~4000 Da or polycaprolactone with a molecular weight of 2000~5000 Da; the auxiliary film-forming agent is hydroxypropyl methylcellulose; and the solvent is a water / ethanol mixture with a volume ratio of 6~7:3~4.

[0009] In a preferred embodiment of the present invention, in step S3, the particle size of the atomized spray is controlled to be 5-20 μm, and the spraying amount is 1-3 g / m 2 , auxiliary wind speed of 0.5~1 m / s.

[0010] In a preferred embodiment of the present invention, in step S1, the processing gas for the plasma treatment is argon or an argon / oxygen mixture, and the volume ratio of the argon / oxygen mixture is 90-95:5-10.

[0011] In a preferred embodiment of the present invention, in step S1, the plasma treatment has a power of 50-150 W, a treatment time of 30-120 s, and a treatment distance of 5-20 mm.

[0012] In a preferred embodiment of the present invention, in step S2, the antistatic agent solution is an aqueous solution or an alcohol aqueous solution of a permanent antistatic agent containing reactive groups, with a concentration of 5-15 wt%.

[0013] In a preferred embodiment of the present invention, the reactive group is one of an epoxy group, an isocyanate group or a siloxane group; the permanent antistatic agent is selected from one of an epoxy-modified polyether antistatic agent, an isocyanate-terminated polyether / polyester antistatic prepolymer or an organosiloxane containing a quaternary ammonium salt group.

[0014] In a preferred embodiment of the present invention, in step S2, the padding method is one dip and one padding, with a liquid padding rate of 70-90%; the pressure of the spraying method is 1-3 bar, and the flow rate is 100-300 mL / min.

[0015] In a preferred embodiment of the present invention, in step S4, the pressure of the high-pressure steam sterilization is 0.1-0.2 MPa, and the time is 8-15 min.

[0016] The present invention provides an antistatic and low-linting surgical drape obtained by any one of the aforementioned surface treatment processes.

[0017] The present invention solves the defects existing in the background technology and has the following beneficial effects: (1) The present invention provides a surface treatment process for surgical drapes with anti-static and low-linting properties. By compounding a low-melting-point polymer with a water-soluble capping agent and combining it with high-pressure steam sterilization, the mobility of low-molecular-weight PEG / PCL molecular segments is enhanced. After contacting the drape surface, they can migrate toward the end along the capillary action of the fiber surface. At the same time, the auxiliary film-forming agent swells instantaneously when exposed to water vapor, guiding the polymer to wrap the breaking point of the fiber end. After cooling, the polymer solidifies to form a micro-spherical mechanical lock, thereby effectively eliminating the source of linting. Compared with the traditional method of reducing linting by increasing the fiber twist or adding adhesives, the physical coating mechanism of the present invention controls linting more thoroughly, thereby further reducing the risk of foreign body reaction or infection caused by linting in the surgical wound.

[0018] (2) In the present invention, by pre-activating the surgical drape with plasma, the surface fibers can generate active free radicals, which can be covalently bonded with the reactive groups on the applied reactive antistatic agent molecules after the heating reaction, so that they are firmly anchored on the fiber surface, thereby forming an antistatic layer that is not easy to fall off, ensuring the durability of the antistatic effect, and overcoming the defect of traditional adsorption-type antistatic agents that are easily migrated and lost due to friction, further ensuring that the drape can stably discharge static charges during use, thereby avoiding static electricity from interfering with the surgical environment and electronic equipment.

[0019] (3) The capping agent solution sprayed on the surface of the drape in the present invention has repeated ether bonds in its PEG molecular chain, which can form hydrogen bonds or van der Waals forces with the active free radicals on the fiber surface after plasma activation. The lone pairs of electrons enriched on the ether oxygen atoms can undergo ion-dipole coupling with the cations of the antistatic layer, thereby widening the charge dissipation channel. It can further adsorb environmental moisture through its ether bonds to form a dynamic hydration layer, thereby increasing the dissipation rate of static charge. The hydrophilicity of PEG complements the charge conduction path of the antistatic agent, and can maintain a low surface resistance even in a dry environment, thereby improving the performance stability of the drape during folding and friction. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are only some embodiments described in the present invention. Those skilled in the art can also derive other drawings based on these drawings without inventive efforts. Figure 1 The present invention is a flowchart of a surface treatment process for anti-static and low-linting surgical drapes according to a preferred embodiment of the present invention. DETAILED DESCRIPTION

[0021] The following will clearly and completely describe the technical solutions in the embodiments of the present invention in conjunction with the accompanying drawings. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts are within the scope of protection of the present invention.

[0022] In the following description, many specific details are set forth to facilitate a full understanding of the present invention. However, the present invention may also be implemented in other ways different from those described herein. Therefore, the scope of protection of the present invention is not limited to the specific embodiments disclosed below.

[0023] It should be noted that the raw materials, equipment, reagents, etc. used in the present invention can be purchased from the market or obtained through existing preparation methods.

[0024] like Figure 1 As shown, a surface treatment process for anti-static and low-linting surgical drapes comprises the following steps: S1. Treat surgical drapes using dielectric barrier discharge plasma. S2. Apply an antistatic agent solution to the sheet treated in step S1 by padding or spraying, and react at 80-120°C for 3-10 minutes; S3. Spraying a capping agent solution uniformly on the surface of the drape treated in step S2 by ultrasonic atomization spraying; the capping agent solution comprises 3-8 wt% of a low melting point polymer, 0.1-0.5 wt% of an auxiliary film-forming agent, and a solvent; S4. The drape treated in step S3 is sterilized by high-pressure steam at 117-125° C. to melt the low-melting-point polymer and migrate to the fiber ends. After cooling, an antistatic and low-linting surgical drape is obtained.

[0025] In some specific embodiments, in step S3, the low melting point polymer is one of polyethylene glycol (PEG) with a molecular weight of 1500~4000 Da or polycaprolactone (PCL) with a molecular weight of 2000~5000 Da; the auxiliary film-forming agent is hydroxypropyl methylcellulose (HPMC); and the solvent is a water / ethanol mixture with a volume ratio of 6~7:3~4.

[0026] In some specific embodiments, in step S3, the particle size of the atomized spray is controlled to be 5-20 μm, and the spraying amount is 1-3 g / m 2 , auxiliary wind speed of 0.5~1 m / s.

[0027] In some specific embodiments, in step S1, the processing gas for plasma treatment is argon or an argon / oxygen mixture, and the volume ratio of the argon / oxygen mixture is 90-95:5-10.

[0028] In some specific embodiments, in step S1, the plasma treatment power is 50-150 W, the treatment time is 30-120 s, and the treatment distance is 5-20 mm.

[0029] In some specific embodiments, in step S2, the antistatic agent solution is an aqueous solution or an alcohol aqueous solution of a permanent antistatic agent containing reactive groups, with a concentration of 5-15 wt%.

[0030] In some specific embodiments, the reactive group is one of epoxy, isocyanate or siloxane; the permanent antistatic agent is selected from one of epoxy-modified polyether antistatic agent, isocyanate-terminated polyether / polyester antistatic prepolymer or organosiloxane containing quaternary ammonium salt group.

[0031] In some specific embodiments, in step S2, the padding method is one dip and one padding, and the liquid padding rate is 70-90%; the pressure of the spraying method is 1-3 bar, and the flow rate is 100-300 mL / min.

[0032] In some specific embodiments, in step S4, the pressure of high-pressure steam sterilization is 0.1-0.2 MPa, and the time is 8-15 min.

[0033] In order to further make the purpose and effect of the present invention simple and easy to understand, the present invention is further described in conjunction with the following specific examples and comparative examples, but the present invention is not limited to the scope of the embodiments.

[0034] It should be noted that in the examples and comparative examples, medical grade polypropylene (PP) spunbond-meltblown composite nonwoven fabric was used as the substrate for the surgical drape, and the substrate weight was 60 g / m 2 , thickness 0.2 mm, fiber diameter 3-4 μm, porosity 85%, surface resistivity 5.1×10 15 Ω / sq; description of the preparation materials is as follows: PEG: molecular weight 2800 Da, purity ≥99.9%, purchased from Jinan Xinke Chemical; PCL: molecular weight 4000 Da, purchased from Dongguan Baojia Plastic; HPMC: purity ≥98%, purchased from Hubei Langbowan Biomedicine; antistatic agent solution: epoxy-modified polyether antistatic agent (polyethylene glycol diglycidyl ether derivative) aqueous solution, purchased from Jinan Century Tongda Chemical. Example 1

[0035] A surface treatment process for anti-static and low-linting surgical drapes comprises the following steps: S1: Dielectric barrier discharge plasma treatment of surgical drapes using an argon / oxygen mixture with a volume ratio of 95:5, a power of 100 W, a treatment time of 60 s, and a treatment distance of 10 mm. S2. Apply an antistatic agent solution to the sheet treated in step S1 by a padding method. The antistatic agent solution is a 10 wt% epoxy-modified polyether antistatic agent aqueous solution. The padding method is performed once for dipping and once for padding, with a padding rate of 80%. The sheet is then reacted at 100° C. for 6 min. S3, through ultrasonic atomization spraying, the end-capping agent solution was sprayed with a particle size of 12 μm and 2 g / m 2 The coating was evenly sprayed on the surface of the drape treated in step S2 at a spraying amount of 0.8 m / s and an auxiliary wind speed of 0.8 m / s. The capping agent solution consisted of 5 wt% PEG, 0.3 wt% HPMC, and a water / ethanol mixed solvent with a volume ratio of 7:3. S4. The drape treated in step S3 was steam sterilized at 121°C and a pressure of 0.15 MPa for 12 min to melt the PEG and migrate to the fiber ends. After cooling, an antistatic and low-linting surgical drape was obtained. Example 2

[0036] This embodiment is basically the same as embodiment 1, except that the low melting point polymer raw material in the end-capping agent solution is different. The specific step of S3 is: the end-capping agent solution is sprayed by ultrasonic atomization with a particle size of 12 μm and a particle size of 2 g / m 2 The coating volume was 0.5 and the auxiliary wind speed was 0.8 m / s, and the coating was evenly sprayed on the surface of the drape treated in step S2; the capping agent solution consisted of 5 wt% PCL, 0.3 wt% HPMC and a water / ethanol mixed solvent with a volume ratio of 7:3. Example 3

[0037] This embodiment is basically the same as embodiment 1, except that the concentration of the low melting point polymer in the end-capping agent solution is different. The specific step of S3 is: the end-capping agent solution is sprayed by ultrasonic atomization with a particle size of 12 μm and a particle size of 2 g / m 2 The coating volume was 0.5 and the auxiliary wind speed was 0.8 m / s, and the coating was evenly sprayed on the surface of the drape treated in step S2; the capping agent solution consisted of 3 wt% PEG, 0.3 wt% HPMC and a water / ethanol mixed solvent with a volume ratio of 7:3. Example 4

[0038] This embodiment is basically the same as embodiment 1, except that the concentration of the low melting point polymer in the end-capping agent solution is different. The specific step of S3 is: the end-capping agent solution is sprayed by ultrasonic atomization with a particle size of 12 μm and a particle size of 2 g / m 2 The coating volume was 0.5 and the auxiliary wind speed was 0.8 m / s, and the coating was evenly sprayed on the surface of the drape treated in step S2; the capping agent solution consisted of 8 wt% PEG, 0.3 wt% HPMC and a water / ethanol mixed solvent with a volume ratio of 7:3. Example 5

[0039] This embodiment is basically the same as embodiment 1, except that the particle size of ultrasonic atomization spraying is different. The specific step of S3 is: ultrasonic atomization spraying is used to spray the end-capping agent solution with a particle size of 5 μm and a particle size of 2 g / m 2 The coating volume was 0.5 and the auxiliary wind speed was 0.8 m / s, and the coating was evenly sprayed on the surface of the drape treated in step S2; the capping agent solution consisted of 5 wt% PEG, 0.3 wt% HPMC and a water / ethanol mixed solvent with a volume ratio of 7:3. Example 6

[0040] This embodiment is basically the same as embodiment 1, except that the particle size of ultrasonic atomization spraying is different. The specific step of S3 is: ultrasonic atomization spraying is used to spray the end-capping agent solution with a particle size of 20 μm and 2 g / m 2 The coating volume was 0.5 and the auxiliary wind speed was 0.8 m / s, and the coating was evenly sprayed on the surface of the drape treated in step S2; the capping agent solution consisted of 5 wt% PEG, 0.3 wt% HPMC and a water / ethanol mixed solvent with a volume ratio of 7:3.

[0041] Comparative Example 1: This comparative example is basically the same as Example 1, except that no plasma, antistatic agent and end-capping agent treatment is performed. Specifically, steps S1, S2 and S3 are omitted, and only step S4 is used for high-pressure steam sterilization.

[0042] Comparative Example 2: This comparative example is substantially the same as Example 1, except that no end-capping agent treatment is performed, specifically, no S3 step is performed.

[0043] Comparative Example 3: This comparative example is basically the same as Example 1, except that the concentration of the low melting point polymer in the end-capping agent solution is different. The specific step of S3 is: by ultrasonic atomization spraying, the end-capping agent solution is sprayed with a particle size of 12 μm and a particle size of 2 g / m 2The coating volume was 0.5 and the auxiliary wind speed was 0.8 m / s, and the coating was evenly sprayed on the surface of the drape treated in step S2; the capping agent solution consisted of 2 wt% PEG, 0.3 wt% HPMC and a water / ethanol mixed solvent with a volume ratio of 7:3.

[0044] Comparative Example 4: This comparative example is basically the same as Example 1, except that the concentration of the low melting point polymer in the end-capping agent solution is different. The specific step of S3 is: by ultrasonic atomization spraying, the end-capping agent solution is sprayed with a particle size of 12 μm and a particle size of 2 g / m 2 The coating volume was 0.5 and the auxiliary wind speed was 0.8 m / s, and the coating was evenly sprayed on the surface of the drape treated in step S2; the capping agent solution consisted of 10 wt% PEG, 0.3 wt% HPMC and a water / ethanol mixed solvent with a volume ratio of 7:3.

[0045] Comparative Example 5: This comparative example is basically the same as Example 1, except that the particle size of the ultrasonic atomization spray is different. The specific step of S3 is: by ultrasonic atomization spraying, the end-capping agent solution is sprayed with a particle size of 3 μm and 2 g / m 2 The coating volume was 0.5 and the auxiliary wind speed was 0.8 m / s, and the coating was evenly sprayed on the surface of the drape treated in step S2; the capping agent solution consisted of 5 wt% PEG, 0.3 wt% HPMC and a water / ethanol mixed solvent with a volume ratio of 7:3.

[0046] Comparative Example 6: This comparative example is basically the same as Example 1, except that the particle size of the ultrasonic atomization spray is different. The specific step of S3 is: by ultrasonic atomization spraying, the end-capping agent solution is sprayed with a particle size of 25 μm and 2 g / m 2 The coating volume was 0.5 and the auxiliary wind speed was 0.8 m / s, and the coating was evenly sprayed on the surface of the drape treated in step S2; the capping agent solution consisted of 5 wt% PEG, 0.3 wt% HPMC and a water / ethanol mixed solvent with a volume ratio of 7:3.

[0047] Comparative Example 7: This comparative example is substantially the same as Example 1, except that no plasma treatment is performed, specifically, no S1 step is performed.

[0048] Comparative Example 8: This comparative example is basically the same as Example 1, except that high-pressure steam sterilization is replaced by hot air curing, and step S4 is specifically as follows: the drape treated in step S3 is hot-air cured at 121°C for 12 minutes, and then cooled to obtain an antistatic, low-linting surgical drape.

[0049] Performance testing: The surgical drapes obtained in Examples 1-6 and Comparative Examples 1-8 were subjected to anti-static and anti-linting performance tests, respectively. The results are shown in Table 1.

[0050] Antistatic: A high resistance meter (model EST121) was used with a three-electrode method (electrode spacing of 5 cm). A DC voltage of 100 V was applied to the sample. The surface resistivity was recorded after standing for 1 min. Five different areas of each sample were tested, and the average value was taken as the resistivity.

[0051] Anti-linting: Using a Martindale abrasion tester (load 500 g), the surgical drape was fixed on the friction table and rubbed 5000 times at a frequency of 120 times / min. The friction products were collected and transferred to a 1m 3 In a closed test chamber, a laser particle counter with a range of 0.5-10 μm was used to collect air in the chamber at a flow rate of 1 L / min for 5 min, and the total number of particles ≥50 μm was recorded. Each sample was tested in parallel three times and the average value was taken.

[0052] Table 1: Surgical drape performance test results of Examples 1-6 and Comparative Examples 1-8

[0053] As shown in Table 1: By comparing Example 1 with Comparative Example 1, it can be seen that in Comparative Example 1, since the antistatic layer and end-capping structure are not introduced, the surface energy of the polypropylene fiber is low, and the lack of active sites leads to the inability to dissipate the charge, and the initial resistivity is as high as 5.0×10 15 Ω / sq, and the fiber ends are not covered, and a large number of them break under friction stress, and the number of falling fluff particles reaches 253 particles / dm 2 , confirming that untreated drapes pose serious risks of electrostatic contamination and falling lint in the surgical environment.

[0054] By comparing Example 1 with Comparative Example 2, it can be seen that after the end-capping agent treatment, although the antistatic layer maintains a low resistivity through covalent grafting, the fiber ends are exposed to mechanical friction, and the β bonds of the polypropylene molecular chains are easily broken during repeated folding, resulting in a surge in the number of falling fibers to 217 particles / dm. 2 After the treatment in Example 1, the number of fallen fluff particles was only 15 particles / dm 2 The microspherical mechanical locks formed by end-capping and solidification can effectively eliminate the source of lint shedding. At the same time, due to the repeated ether bonds in the PEG molecular chain, they can form hydrogen bonds or van der Waals forces with the active free radicals on the fiber surface after plasma activation, broadening the charge dissipation channel and increasing the dissipation rate of static charge. After the end-capping agent treatment is missing, the resistivity also increases to 6.2×10 9 Ω / sq.

[0055] By comparing Example 1 and Examples 3-4 with Comparative Example 3-4, it can be seen that when the concentration of the low-melting-point polymer in the capping agent is in the range of 3-8 wt%, PEG forms a dynamic melt during high-pressure steam sterilization, and its ether bond forms hydrogen bonds with the hydroxyl groups on the fiber surface, guiding the molecular chain to migrate along the fiber axis to the end. Each PEG molecule contains about 68 ether bond units, which are wrapped around the fiber breakage point through van der Waals forces and form a microsphere anchoring structure after cooling, thereby stabilizing the number of falling fluff particles at 15-37 particles / dm 2 ; When the concentration of the low melting point polymer in the end-capping agent of Comparative Example 3 was reduced to 2 wt%, the density of the PEG segments was insufficient to completely cover the fiber end breakage points, and the falling lint increased to 104 particles / dm 2 In contrast, when the concentration of the low-melting-point polymer in the capping agent of Comparative Example 4 was increased to 10 wt%, the high concentration of PEG resulted in excessive film formation, and cracks formed after the solvent evaporated, resulting in an increase in the number of falling particles to 61 particles / dm 2 , and the film layer hinders the electrostatic charge conduction path, and the resistivity rises to 2.1×10 9 Ω / sq.

[0056] By comparing Example 1 and Examples 5-6 with Comparative Examples 5-6, it can be seen that: the appropriate atomized particle size can penetrate into the fiber gaps without penetrating into the interior of the monofilament, ensuring that PEG only migrates on the surface and evenly covers the fiber surface; when the atomized spray particle size is reduced to 3 μm, the droplets are too small to penetrate into the interior of the fiber. During high-pressure steam sterilization, PEG preferentially fills the pores rather than migrates to the ends, resulting in a decrease in the coverage rate and an increase in the number of falling flocculation particles to 89 particles / dm 2 When the atomized spray particle size increases to 25 μm, oversized droplets accumulate on the surface to form a film, the droplet penetration decreases, and subsequent steam sterilization penetration is hindered. HPMC does not swell sufficiently, resulting in the deviation of the PEG migration path and a decrease in the terminal coverage rate.

[0057] By comparing Example 1 with Comparative Example 7, it can be seen that when no plasma treatment is performed, the surface of the polypropylene fiber contains only inert methyl groups, which cannot react with the epoxy groups of the antistatic agent through ring-opening. The antistatic agent is only attached to the fiber surface by physical adsorption, and the resistivity increases to 8.2×10 10 Ω / sq, and the unactivated fiber surface hinders the hydrogen bonding of PEG, resulting in failure in fluff control.

[0058] By comparing Example 1 with Comparative Example 8, it can be seen that after high-pressure steam sterilization is replaced by hot air curing, the number of falling lint particles increases from 15 particles / dm 2 Increased to 63 particles / dm 2In the steam environment, the HPMC auxiliary film-forming agent swells instantly when encountering water vapor, guiding the migration of PEG / PCL along the fiber surface by capillary action. However, hot air curing causes the solvent to evaporate rapidly, restricting the movement of polymer chain segments and only forming a discontinuous coating on the fiber surface, which is difficult to effectively wrap the end breaking point.

[0059] The above description is based on the ideal embodiment of the present invention. It will be apparent to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above, and that the present invention can be implemented in other specific forms without departing from the spirit or essential characteristics of the present invention. Therefore, the embodiments should be considered as illustrative and non-restrictive in all respects. The scope of the present invention is defined by the appended claims, not the foregoing description, and it is intended that all variations within the meaning and range of equivalents of the claims be encompassed within the present invention. Any reference signs in the claims should not be construed as limiting the claim to which they relate.

[0060] In addition, it should be understood that although this specification is described in terms of implementation methods, not every implementation method contains only one independent technical solution. This narrative method of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment can also be appropriately combined to form other implementation methods that can be understood by those skilled in the art.

Claims

1. A surface treatment process for anti-static and low-linting surgical drapes, characterized in that: The following steps are involved: S1. Treat surgical drapes using dielectric barrier discharge plasma. S2. Apply an antistatic agent solution to the sheet treated in step S1 by padding or spraying, and react at 80-120°C for 3-10 minutes; S3. Spraying a capping agent solution uniformly on the surface of the drape treated in step S2 by ultrasonic atomization spraying; the capping agent solution comprises 3-8 wt% of a low melting point polymer, 0.1-0.5 wt% of an auxiliary film-forming agent, and a solvent; S4. The drape treated in step S3 is sterilized by high-pressure steam at 117-125° C. to melt the low-melting-point polymer and migrate to the fiber ends. After cooling, an antistatic and low-linting surgical drape is obtained.

2. The surface treatment process for anti-static and low-linting surgical drape according to claim 1, characterized in that: In step S3, the low melting point polymer is one of polyethylene glycol with a molecular weight of 1500-4000 Da or polycaprolactone with a molecular weight of 2000-5000 Da; the auxiliary film-forming agent is hydroxypropyl methylcellulose; and the solvent is a water / ethanol mixture with a volume ratio of 6-7:3-4.

3. The surface treatment process for anti-static and low-linting surgical drape according to claim 1, characterized in that: In the step S3, the particle size of the atomized spray is controlled to be 5-20 μm, and the spraying amount is 1-3 g / m 2 , auxiliary wind speed of 0.5~1 m / s.

4. The surface treatment process for anti-static and low-linting surgical drape according to claim 1, characterized in that: In the step S1, the processing gas for the plasma treatment is argon or an argon / oxygen mixed gas, and the volume ratio of the argon / oxygen mixed gas is 90-95:5-10.

5. The surface treatment process for anti-static and low-linting surgical drape according to claim 1, characterized in that: In step S1, the plasma treatment has a power of 50-150 W, a treatment time of 30-120 s, and a treatment distance of 5-20 mm.

6. The surface treatment process for anti-static and low-linting surgical drape according to claim 1, characterized in that: In step S2, the antistatic agent solution is an aqueous solution or an alcohol aqueous solution of a permanent antistatic agent containing reactive groups, with a concentration of 5 to 15 wt%.

7. The surface treatment process for anti-static and low-linting surgical drape according to claim 6, characterized in that: The reactive group is one of epoxy, isocyanate or siloxane; the permanent antistatic agent is selected from one of epoxy-modified polyether antistatic agent, isocyanate-terminated polyether / polyester antistatic prepolymer or organosiloxane containing quaternary ammonium salt group.

8. The surface treatment process for anti-static and low-linting surgical drape according to claim 1, characterized in that: In step S2, the padding method is one dip and one padding, with a liquid padding rate of 70-90%; the pressure of the spraying method is 1-3 bar, and the flow rate is 100-300 mL / min.

9. The surface treatment process for anti-static and low-linting surgical drape according to claim 1, characterized in that: In step S4, the pressure of the high-pressure steam sterilization is 0.1-0.2 MPa, and the time is 8-15 minutes.

10. An antistatic, low-linting surgical drape, characterized by: Obtained by the surface treatment process according to any one of claims 1 to 9.

Images